Abstract:Numerous practical issues must be considered when combining targeted therapies in early clinical drug development. These include tumor resistance mechanisms, the existence of multiple, redundant signaling pathways, and the failure of single-agent therapies to achieve cures. The strategies adopted to examine combinatorial therapy include the goal of hitting more than one target by specifically inhibiting signal transduction cascades and suppressing specific mechanisms of action with the use of multitargeted kinase inhibitors made possible by high-throughput screening techniques, combinatorial chemistry, and chemoinformatics. Two complex considerations are: which agents to combine given the heterogeneity of tumors and their various underlying perturbations, including secondary mutations and feedback loops, and how to translate findings from the bench to the bedside or directly from the bedside. Another consideration is: When is there enough information to provide a rationale for instituting a phase I trial? Various strategies have been used in combining molecules, including targeting diverse pathways, inhibiting upstream and downstream signals, and adopting a synthetic lethality paradigm. Other issues are: determining appropriate target populations for treatment, how to combine therapeutics with diagnostics, and the frequency of targets in patients referred to clinical trials. Here, we review these issues and we propose various novel trial designs that are logical for determining the efficacy of a drug or drug combination for personalized treatment. A difficult issue that must be answered is how many and which drugs to combine. Recent technologies, such as multiplexed assay platforms and bioinformatics, will shape the future of clinical trials and help answer these questions surrounding combinatorial treatment.

Molecular-targeted agents combination therapy for cancer: developments and potentials

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Combination Treatment Including Targeted Therapy for Advanced Hepatocellular Carcinoma.

Rational combinations of targeted cancer therapies: background, advances and challenges

Combination antitumor therapy with targeted dual-nanomedicines

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Drug Combination in Clinical Cancer Treatments

Multifunctional nano MOF drug delivery platform in combination therapy

Molecularly targeted cancer therapy: some lessons from the past decade

Prospects for combining targeted and conventional cancer therapy with immunotherapy

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

Nanotechnology for Multimodal Synergistic Cancer Therapy

Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer.

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC

Combining targeted therapies: practical issues to consider at the bench and bedside

Molecular targeted therapy for anticancer treatment